Zhejiang Hisun Pharmaceutical has been granted a patent for indazole derivatives as IRAK4 inhibitors. The compounds of formula (I) are provided along with their preparation method and therapeutic use. GlobalData’s report on Zhejiang Hisun Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

According to GlobalData’s company profile on Zhejiang Hisun Pharmaceutical, Cancer treatment biomarkers was a key innovation area identified from patents. Zhejiang Hisun Pharmaceutical's grant share as of February 2024 was 66%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11897863B2) discloses a compound of formula (I) and its various forms, including stereoisomers, tautomers, and pharmaceutically acceptable salts. The patent also covers the compound's structures of formula (III), (IV), (Va), (Vb), and (Vc), along with pharmaceutical compositions containing these compounds and optional carriers. Additionally, the patent claims methods for inhibiting IRAK4 kinase activity and preventing or treating autoimmune diseases, inflammatory diseases, or cancers by administering the disclosed compounds to subjects in need.

Furthermore, the patent specifies the use of the pharmaceutical composition for inhibiting IRAK4 kinase activity and preventing or treating autoimmune diseases, inflammatory diseases, or cancers. The methods outlined in the patent target a range of conditions such as lymphoma, endometriosis, psoriasis, lupus erythematosus, multiple sclerosis, and rheumatoid arthritis, including specific subtypes like primary central nervous system lymphoma or diffuse large B-cell lymphoma with MYD88 L265P mutation. Overall, the patent provides a comprehensive framework for utilizing the disclosed compound and its various forms in therapeutic applications related to IRAK4 kinase activity and associated diseases.

To know more about GlobalData’s detailed insights on Zhejiang Hisun Pharmaceutical, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies